Literature DB >> 21448176

High drug attrition rates--where are we going wrong?

Lisa Hutchinson, Rebecca Kirk.   

Abstract

Mesh：

Year:  2011        PMID： 21448176     DOI： 10.1038/nrclinonc.2011.34

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  160 in total

1.  Drug development: Raise standards for preclinical cancer research.

Authors:  C Glenn Begley; Lee M Ellis
Journal:  Nature       Date:  2012-03-28       Impact factor: 49.962

Review 2.  Engineered heart tissues and induced pluripotent stem cells: Macro- and microstructures for disease modeling, drug screening, and translational studies.

Authors:  Evangeline Tzatzalos; Oscar J Abilez; Praveen Shukla; Joseph C Wu
Journal:  Adv Drug Deliv Rev       Date:  2015-09-30       Impact factor: 15.470

Review 3.  Humanized mice for immune checkpoint blockade in human solid tumors.

Authors:  Henry Yip; Carl Haupt; Grace Maresh; Xin Zhang; Li Li
Journal:  Am J Clin Exp Urol       Date:  2019-10-15

Review 4.  Reproducibility of research and preclinical validation: problems and solutions.

Authors:  Lajos Pusztai; Christos Hatzis; Fabrice Andre
Journal:  Nat Rev Clin Oncol       Date:  2013-10-01       Impact factor: 66.675

Review 5.  Appraising iniparib, the PARP inhibitor that never was--what must we learn?

Authors:  Joaquin Mateo; Michael Ong; David S P Tan; Michael A Gonzalez; Johann S de Bono
Journal:  Nat Rev Clin Oncol       Date:  2013-10-15       Impact factor: 66.675

6.  Nanoemulsion formulation of a novel taxoid DHA-SBT-1214 inhibits prostate cancer stem cell-induced tumor growth.

Authors:  Gulzar Ahmad; Rana El Sadda; Galina Botchkina; Iwao Ojima; James Egan; Mansoor Amiji
Journal:  Cancer Lett       Date:  2017-08-11       Impact factor: 8.679

7.  Preclinical predictors of anticancer drug efficacy: critical assessment with emphasis on whether nanomolar potency should be required of candidate agents.

Authors:  C C Wong; Ka-Wing Cheng; Basil Rigas
Journal:  J Pharmacol Exp Ther       Date:  2012-03-23       Impact factor: 4.030

8.  High-Content Screening Comparison of Cancer Drug Accumulation and Distribution in Two-Dimensional and Three-Dimensional Culture Models of Head and Neck Cancer.

Authors:  Feng Shan; David A Close; Daniel P Camarco; Paul A Johnston
Journal:  Assay Drug Dev Technol       Date:  2017-12-07       Impact factor: 1.738

9.  Expansion of patient-derived circulating tumor cells from liquid biopsies using a CTC microfluidic culture device.

Authors:  Bee Luan Khoo; Gianluca Grenci; Ying Bena Lim; Soo Chin Lee; Jongyoon Han; Chwee Teck Lim
Journal:  Nat Protoc       Date:  2017-12-07       Impact factor: 13.491

10.  Metabolic reprogramming and validation of hyperpolarized 13C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor.

Authors:  Kayvan R Keshari; Renuka Sriram; Mark Van Criekinge; David M Wilson; Zhen J Wang; Daniel B Vigneron; Donna M Peehl; John Kurhanewicz
Journal:  Prostate       Date:  2013-03-26       Impact factor: 4.104
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.